GenomeDx Biosciences seals multiple insurance deals for prostate cancer Dx

San Diego's GenomeDx Biosciences said it has sealed deals with three major insurers to cover the company's Decipher test, which measures a patient's risk of metastatic prostate cancer. Stratose, Three Rivers Provider Network and Fortified Provider Network--all PPOs--agreed to count the company and its test as a participating provider. Combined, the insurers cover more than 62.6 million people, the company said. GenomeDx, which launched in 2008, must still secure CMS coverage for the $4,250 test. Insurance reimbursement is the last major milestone diagnostics companies target when they launch new products. Item